Whitehawk Therapeutics, Inc. (NASDAQ:WHWK) Receives Consensus Recommendation of “Moderate Buy” from Analysts

Shares of Whitehawk Therapeutics, Inc. (NASDAQ:WHWK) have been given a consensus rating of “Moderate Buy” by the eight brokerages that are covering the company, Marketbeat reports. One analyst has rated the stock with a sell recommendation, one has issued a hold recommendation and six have assigned a buy recommendation to the company. The average 1 year price target among brokerages that have covered the stock in the last year is $8.20.

A number of equities analysts have recently issued reports on the stock. Citigroup initiated coverage on shares of Whitehawk Therapeutics in a research note on Thursday, April 16th. They issued an “outperform” rating for the company. Citizens Jmp assumed coverage on shares of Whitehawk Therapeutics in a research report on Thursday, April 16th. They set a “market outperform” rating and a $8.00 price target on the stock. Oppenheimer reissued an “outperform” rating and issued a $7.00 target price on shares of Whitehawk Therapeutics in a research note on Friday, May 8th. Leerink Partners started coverage on shares of Whitehawk Therapeutics in a research note on Monday, July 13th. They set an “outperform” rating and a $9.00 price target for the company. Finally, Weiss Ratings cut Whitehawk Therapeutics from a “sell (d)” rating to a “sell (d-)” rating in a report on Friday, June 5th.

Whitehawk Therapeutics Price Performance

Whitehawk Therapeutics stock opened at $3.85 on Friday. The firm’s 50 day simple moving average is $4.15 and its 200-day simple moving average is $3.73. Whitehawk Therapeutics has a fifty-two week low of $1.57 and a fifty-two week high of $5.49. The company has a market cap of $190.39 million, a P/E ratio of -2.29 and a beta of 0.77.

Whitehawk Therapeutics (NASDAQ:WHWK) last posted its quarterly earnings results on Thursday, May 7th. The company reported ($0.32) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.36) by $0.04. On average, analysts expect that Whitehawk Therapeutics will post -1.37 EPS for the current fiscal year.

Institutional Inflows and Outflows

Hedge funds have recently bought and sold shares of the stock. Eversept Partners LP acquired a new stake in Whitehawk Therapeutics during the 4th quarter valued at $630,000. Citadel Advisors LLC acquired a new position in shares of Whitehawk Therapeutics during the 3rd quarter worth $266,000. ADAR1 Capital Management LLC acquired a new position in Whitehawk Therapeutics during the 4th quarter worth approximately $188,000. Jane Street Group LLC raised its position in Whitehawk Therapeutics by 177.3% in the fourth quarter. Jane Street Group LLC now owns 69,931 shares of the company’s stock valued at $169,000 after purchasing an additional 44,716 shares during the last quarter. Finally, Marshall Wace LLP acquired a new position in shares of Whitehawk Therapeutics during the fourth quarter worth $164,000. 52.08% of the stock is currently owned by institutional investors.

About Whitehawk Therapeutics

Aadi Bioscience, Inc, a clinical-stage biopharmaceutical company, engages in developing and commercializing precision therapies for genetically defined cancers with alterations in mTOR pathway genes. Its lead drug candidate, FYARRO is a form of sirolimus bound to albumin. Aadi is evaluating FYARRO in cancers with known mTOR pathway activation, including tumor agnostic indications targeting specific genomic alterations that activate the mTOR pathway. The company was incorporated in 2007 and is headquartered in Pacific Palisades, California.